Search

Your search keyword '"CIU, chronic idiopathic urticaria"' showing total 4 results
Start Over Descriptor "CIU, chronic idiopathic urticaria"
4 results on '"CIU, chronic idiopathic urticaria"'

1. Chronic urticarial plaques in a young woman

Author

Suzanne C. Ward and Nathan W. Rojek

Subjects
medicine.medical_specialty, business.industry, Dermatology, chronic urticaria, autoinflammatory syndromes, genodermatoses, FCAS, familial cold autoinflammatory syndrome, Familial Cold Autoinflammatory Syndrome, RL1-803, Images in Dermatology, Medicine, Chronic idiopathic urticaria, periodic fever syndromes, business, CIU, chronic idiopathic urticaria, Chronic urticaria
Published
2021

2. Linear IgA bullous dermatosis successfully treated with omalizumab: A case report

Author

Nadine S. Maalouf and Dominique Hanna

Subjects
medicine.medical_specialty, Linear IgA bullous dermatosis, Case Report, Dermatology, Omalizumab, Immunoglobulin E, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Erythematous plaque, bullous dermatosis, Herpetiform, Bullous disease, Medicine, skin and connective tissue diseases, CIU, chronic idiopathic urticaria, IgE, immunoglobulin E, integumentary system, biology, treatment, business.industry, LABD, linear IgA bullous dermatosis, medicine.disease, eye diseases, monoclonal anti-IgE antibody, 030220 oncology & carcinogenesis, Monoclonal, biology.protein, omalizumab, sense organs, Chronic idiopathic urticaria, IgE, linear IgA bullous dermatosis, business, medicine.drug
Abstract

Linear IgA bullous dermatosis (LABD) is a rare autoimmune bullous disease characterized by linear deposition of IgA along the cutaneous basement membrane. Clinically, LABD has a variable presentation characterized by tense vesiculobullous lesions on the trunk and extremities that often appear in a herpetiform arrangement or at the center of annular erythematous plaques. Omalizumab (Xolair; Genentech, South San Francisco, CA) is a monoclonal anti–immunoglobulin E (IgE) antibody that has been approved for chronic idiopathic urticaria (CIU). To date, omalizumab has not been reported to be of benefit in the treatment of LABD. However, omalizumab has been reported to improve control of other bullous dermatoses, particularly bullous pemphigoid.1

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results